Shingrix – Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 57-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (Patient received first dose in 2021). On 01-NOV-2024, the patient received the 2nd dose of Shingrix. On 01-NOV-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix – Late second dose). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 10-JAN-2025 Pharmacist mentioned that a patient received the first dose of Shingrix in 2021 and second dose was given on 01-NOV-2024. The pharmacist asked if the patient should receive a third dose. The reporter did not share information about Shingrix doses such as lot number and expiration date. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.